"More recently, the United States patent office fast-tracked a patent in his name for defense against neurological disease. This patent will be a lead project to be developed by SeD BioMed Inc."

Looks like this is one of the assets SeD will look to develop through Amarantus. Judging by Thompson's track record with Emulin, not a bad shot on goal.